The genetic testing services provider has added a Samsung-led second close to a $23m first tranche that included a range of corporate investors.
Consumer electronics producer Samsung’s Catalyst Fund has led the $14m second tranche of a series B round for US-based genomic testing telemedicine service Genome Medical that now totals $37m.
Genome Medical’s telemedicine service guides patients to suitable tests to genetic testing and experts that can help them navigate the process. The funding will go to technology development.
The June 2019 first close was led by Echo Health Ventures, a partnership between healthcare provider Cambia Health Solutions and health insurer…
